Search | Clinical Trials Finder

Conditions: Menopause
Interventions: Estradiol vaginal ring, Placebo vaginal ring; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 89 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breastfeeding, Postpartum Sexual Dysfunction, Vaginal Atrophy
Interventions: Estradiol, Vaginal Moisturizer; Drug · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrophic Vaginitis, Breast Cancer
Interventions: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Estrogen Levels Among Breast Cancer Patients
Interventions: Estradiol; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Postmenopausal Symptoms
Interventions: Estrogel, Placebo; Drug · Other
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Premenstrual Syndrome, Menstruation Disturbances
Interventions: Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prepubertal Labial Adhesions
Interventions: Estradiol cream 0.01%, Cetaphil; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 3 Months to 12 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions: SexHealth II, Contraceptive; Behavioral · Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions: Estradiol, placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions: Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin; Drug · Procedure · Behavioral + 1 more
Lead sponsor: Jocelyn Fitzgerald; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Menopause, Postmenopausal Vaginal Atrophy
Interventions: estradiol, 10 mcg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 51
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more

Conditions: Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions: Vaginal estradiol tablets, Vaginal moisturizer; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer, Hot Flashes, Menopausal Symptoms
Interventions: conjugated estrogens, medroxyprogesterone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 24
States / cities: Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Atrophic Vaginitis
Interventions: Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Suppression of Ovulation
Interventions: Nestorone®/Estradiol Contraceptive Vaginal Ring; Device
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Sacramento, California • New York, New York • Cincinnati, Ohio + 4 more

Conditions: Suppression of Ovulation
Interventions: 10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more

Conditions: Estrogen Receptor Positive Breast Cancer, Breast Cancer
Interventions: ESTRING, Replens, Vagifem; Drug
Lead sponsor: Polly A. Niravath, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Contraception
Interventions: ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Atrophic Vaginitis Due to Menopause
Interventions: Estradiol Vaginal Tablets 10 mcg, placebo; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Huntsville, Alabama • Montgomery, Alabama • San Diego, California + 19 more

Conditions: Vaginosis, Bacterial
Interventions: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk), Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark); Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Mahwah, New Jersey

Conditions: HIV Prevention
Interventions: Tenofovir 1% gel, Vaginal product; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: San Francisco, California • The Bronx, New York

Conditions: Genitourinary Syndrome of Menopause (GSM)
Interventions: Revaree, Estrace; Device · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrophic Vaginitis
Interventions: Estriol, Estradiol valerate, Vanicream Lite; Drug
Lead sponsor: Maire Mac Bride; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Estrogen and the Urogenital Microbiome in GSM

Postpartum Vaginal Estrogen for Breastfeeding Patients

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Estradiol Levels in Patients Treated With Estring

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

A Treatment Study for Premenstrual Syndrome (PMS)

Treatment of Prepubertal Labial Adhesions

Inpatient Adolescent Contraception

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause

A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis